← SynDRA
ZIMLOVISERTIB
SynDRA canonical compound SYN0039262 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | IRAK4 |
|---|
| Mechanism of action | kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- IRAK4 INHIBITOR
- Interleukin-1 receptor-associated kinase 4 inhibitor
- kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- KDR
- SYK
- ABL1
- PDK1
- PIK3C2A
- PI4KB
- PI4KAP2
- PI4KA
- PI4K2B
- PHKG2
- PHKG1
- PDGFRB
- PIK3C3
- PDGFRA
- PASK
- PAN3
- PAK6
- PAK3
- PAK2
- PAK1
- OXSR1
- PIK3C2B
- PIK3CA
- NUAK1
- PIK3CB
- PRKCE
- PRKCD
- PRKCB
- PRKCA
- PRKAA2
- PRKAA1
- PLK3
- PLK2
- PLK1
- PKN2
- PKN1
- PKD1
- PIP4K2C
- PIP4K2B
- PIP4K2A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- PF-06650833
- PF06650833
- ZIMLOVISERTIB (PF-06650833)
- PF 06650833
- S3F315JJXI
- RefChem:195974
- Zimlovisertib [USAN]
- MFCD30343869
- Zimlovisertib (USAN)
- 8CG
- Zimlovisertib [WHO-DD]
- UNII-S3F315JJXI
- ZIMLOVISERTIB [INN]
- GTPL9667
- orb1296160
- SCHEMBL17136792
- SCHEMBL29361300
- GLXC-10290
- Zimlovisertib (PF-06650833)
- EX-A2502
- BDBM50239499
- WHO 12020
- US10329302, Example 344
- US10793579, Example 374
- US11702424, Example 374
- AKOS030528051
- CS-6078
- EBC-412094
- compound 40 [PMID: 28498658]
- NCGC00510500-03
- AC-35759
- DA-76775
- HY-19836
- SY045278
- D12167
- PF06650833, >=98% (HPLC)
Look up ZIMLOVISERTIB in the interactive SynDRA portal →